Interní Med. 2018; 20(4): 183-188 | DOI: 10.36290/int.2018.033

Prediabetes

prof. MUDr. Kateřina Štechová, Ph.D.
Interní klinika UK 2. LF a FN v Motole, Praha

Prediabetes (impaired glucose homeostasis) is clinically silent period preceding overt diabetes. Increased fasting glycaemia and/or higher glycaemia after glucose load are observed but glycaemia values do not reach the threshold diagnostic for diabetes.Currently prediabetes is not considered to be a specific clinical entity (disease) despite the evidence documenting that “toxic cardio-metabolic” processes during prediabetes are harmful and may for instance initiate the development of chronic microvascularcomplications. In prediabetes pathogenesis the development of insulin resistance is crucial. First step towards the development ofinsulin resistance may occur already in utero. Maternal metabolic status can initiate insulin resistance in foetal brain with importantconsequences later during postnatal life. To prevent the progression of impaired glucose homeostasis into diabetes life stylemodifications (healthy diet, physical activity) are considered now to be superior over drugs targeting insulin resistance despiteknown problems with adherence. In the article current concept of prediabetes pathogenesis, its importance, new biomarkersand preventive (therapeutic) possibilities are further discussed.

Keywords: diabetes, fetal programming, insulin resistance, obesity, prediabetic state

Published: October 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štechová K. Prediabetes. Interní Med. 2018;20(4):183-188. doi: 10.36290/int.2018.033.
Download citation

References

  1. IDF Diabetes Atlas 8th Edition (2017) https://www.idf.org/e-library/epidemiology-research/diabetes-atlas.html, 19. 6. 2018
  2. http://www.uzis.cz/katalog/zdravotnicka-statistika/pece-nemocne-cukrovkou, 19. 6. 2018
  3. Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp Biol Med (Maywood). 2016 Jun; 241(12): 1323-1331. Go to original source... Go to PubMed...
  4. Pelikánová T. Klasifikace a patogeneza diabetu. V: Pelikánová T, Bartoš V a kol. Praktická diabetologie. 6. aktualizované a doplněné vydání. Maxdorf, s. r. o., Praha, 2018: s. 60-131.
  5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7; 346(6): 393-403. Go to original source... Go to PubMed...
  6. Bartoš V. Základní poznatky o diabetu. V: Pelikánová T, Bartoš V a kol. Praktická diabetologie. 6.aktualizované a doplněné vydání. Maxdorf, s. r. o., Praha, 2018: s.12-59.
  7. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA. 2004 Feb 11; 291(6): 711-717. Go to original source... Go to PubMed...
  8. Vaishya S, Sarwade RD, Seshadri V. MicroRNA, Proteins, and Metabolites as Novel Biomarkers for Prediabetes, Diabetes, and Related Complications. Front Endocrinol (Lausanne). 2018 Apr 23; 9: 180. doi: 10.3389/fendo.2018.00180.eCollection 2018. Go to original source... Go to PubMed...
  9. Yi F, Brubaker PL, Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta.J Biol Chem. 2005 Jan 14; 280(2): 1457-1464. Go to original source... Go to PubMed...
  10. Häring HU. Novel phenotypes of prediabetes? Diabetologia. 2016 Sep; 59(9): 1806-1818 Go to original source... Go to PubMed...
  11. Stefan N, Häring HU. The metabolically benign and malignant fatty liver. Diabetes. 2011 Aug; 60(8): 2011-2017. Go to original source... Go to PubMed...
  12. Stefan N, Häring HU, Hu FB, Schulze MB.Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013 Oct; 1(2): 152-162. Go to original source... Go to PubMed...
  13. Wagner R, Machann J, Lehmann R, Rittig K, Schick F, Lenhart J, Artunc F, Linder K, Claussen CD, Schleicher E, Fritsche A, Häring HU, Weyrich P. Exercise-induced albuminuria is associated with perivascular renal sinus fat in individuals at increased risk of type 2 diabetes. Diabetologia. 2012 Jul; 55(7): 2054-2058. Go to original source... Go to PubMed...
  14. Heni M, Machann J, Staiger H, Schwenzer NF, Peter A, Schick F, Claussen CD, Stefan N, Häring HU, Fritsche A. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study. Diabetes Metab Res Rev. 2010 Mar; 26(3): 200-205. Go to original source... Go to PubMed...
  15. Kullmann S, Heni M, Veit R, Scheffler K, Machann J, Häring HU, Fritsche A, Preissl H. Selective insulin resistance in homeostatic and cognitive control brain areas in overweight and obese adults. Diabetes Care. 2015 Jun; 38(6): 1044-1050. Go to original source... Go to PubMed...
  16. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007 Feb; 24(2): 137-144. Go to original source... Go to PubMed...
  17. Guasch-Ferré M, Hruby A, Toledo E, Clish CB, Martínez-González MA, Salas-Salvadó J, Hu FB. Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis. Diabetes Care. 2016 May; 39(5): 833-846. Go to original source... Go to PubMed...
  18. Kolberg JA, J?rgensen T, Gerwien RW, Hamren S, McKenna MP, Moler E, Rowe MW, Urdea MS, Xu XM, Hansen T, Pedersen O, Borch-Johnsen K. Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort.Diabetes Care. 2009 Jul; 32(7): 1207-1212. Go to original source... Go to PubMed...
  19. Shoukry A, Bdeer Sel-A, El-Sokkary RH. Urinary monocyte chemoattractant protein-1 and vitamin D-binding protein as biomarkers for early detection of diabetic nephropathy in type 2 diabetes mellitus. Mol Cell Biochem. 2015 Oct; 408(1-2): 25-35. Go to original source... Go to PubMed...
  20. Hostalek U, Gwilt M, Hildemann S. Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs. 2015 Jul; 75(10): 1071-1094. Go to original source... Go to PubMed...
  21. Kerrison G, Gillis RB, Jiwani SI, Alzahrani Q, Kok S, Harding SE, Shaw I, Adams GG. The Effectiveness of Lifestyle Adaptation for the Prevention of Prediabetes in Adults: A Systematic Review. J Diabetes Res. 2017; 2017: 8493145. doi: 10.1155/2017/8493145. Epub 2017 Apr 16. Go to original source... Go to PubMed...
  22. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002 Dec; 25(12): 2165-2171. Go to original source... Go to PubMed...
  23. Southwick SM, Vythilingam M, Charney DS. The psychobiology of depression and resilience to stress: implications for prevention and treatment. Annu Rev Clin Psychol. 2005; 1: 255-291. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.